Draupnir Bio
Risskov
About Draupnir Bio
Draupnir Bio intends to develop a new type of cholesterol-lowering medicine that prevents blood clots in the heart more effectively than the current medicine. The company is developing a platform for exploring the glycome to develop novel therapeutics, based on array technology, protein chemistry, and advanced carbohydrate chemistry. The company is able to synthesize, screen, and select highly potent and specific heparan sulfate glycomimetic drug candidates in cardiovascular, inflammatory, and infectious diseases.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $10M+
- Total funding: $46.2M
- Funding stage: Seed
- Last round: Seed (Jul 2024)
- Website: draupnir.bio
Industries & Categories
Biotechnology, Health Care, Pharmaceutical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/draupnir-bio-140581 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.